Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors

被引：35

作者：

Beck, Hilary P. ^{[1
]}

DeGraffenreid, Michael ^{[1
]}

Fox, Brian ^{[1
]}

Allen, John G. ^{[2
]}

Rew, Yosup ^{[1
]}

Schneider, Stephen ^{[3
]}

Saiki, Anne Y. ^{[4
]}

Yu, Dongyin ^{[4
]}

Oliner, Jonathan D. ^{[4
]}

Salyers, Kevin ^{[5
]}

Ye, Qiuping ^{[6
]}

Olson, Steven ^{[1
]}

机构：

[1] Amgen Inc, Chem Res & Discovery, San Francisco, CA 94080 USA

[2] Amgen Inc, Chem Res & Discovery, Thousand Oaks, CA 91320 USA

[3] Amgen Inc, Chem Res & Discovery, Cambridge, MA 02142 USA

[4] Amgen Inc, Oncol Res, Thousand Oaks, CA 91320 USA

[5] Amgen Inc, PKDM, Thousand Oaks, CA 91320 USA

[6] Amgen Inc, PKDM, San Francisco, CA 94080 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 09期

关键词：

Oncology; Protein-protein interaction; Pharmacokinetics; SMALL-MOLECULE INHIBITORS; CANCER-THERAPY; P53; AMPLIFICATION; APOPTOSIS; STABILITY; BINDING;

D O I：

10.1016/j.bmcl.2010.11.027

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Human murine double minute 2 (MDM2) is a negative regulator of p53, which plays an important role in cell cycle and apoptosis. We report several optimizations to the synthesis of the chromenotriazolopyrimidine series of MDM2-p53 protein-protein interaction inhibitors. Additionally, the in vitro and in vivo stability, pharmacokinetic properties and solubility were improved through N-substitution. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：2752 / 2755

页数：4

共 50 条

[31] Identification of a disruptor of the MDM2-p53 protein-protein interaction facilitated by high-throughput in silico docking
Lawrence, Harshani R.
Li, Zhenyu
Yip, M. L. Richard
Sung, Shen-Shu
Lawrence, Nicholas J.
McLaughlin, Mark L.
McManus, Gregory J.
Zaworotko, Michael J.
Sebti, Said M.
Chen, Jiandong
Guida, Wayne C.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (14) : 3756 - 3759
[32] Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction
Beloglazkina, Anastasia
Zyk, Nikolai
Majouga, Alexander
Beloglazkina, Elena
MOLECULES, 2020, 25 (05):
[33] The synthesis and characterization of tetramic acid derivatives as Mdm2-p53 inhibitors
Muszak, Damian
Labuzek, Beata
Brela, Mateusz Z.
Twarda-Clapa, Aleksandra
Czub, Miroslawa
Musielak, Bogdan
Surmiak, Ewa
Holak, Tad A.
JOURNAL OF MOLECULAR STRUCTURE, 2019, 1189 : 161 - 174
[34] Insight on Heterocycles as p53-MDM2 Protein-Protein Interaction Inhibitors: Molecular Mechanism for p53 Activation
Basha, N. Jeelan
Mohan, R. M.
CHEMISTRYSELECT, 2024, 9 (10):
[35] An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors
Xue, Xin
Bao, Gang
Zhang, Hai-Qing
Zhao, Ning-Yi
Sun, Yuan
Zhang, Yue
Wang, Xiao-Long
MOLECULES, 2018, 23 (12):
[36] Discovery of Potent and Selective p53-MDM2 Protein-Protein Interaction Inhibitors as Anticancer Drugs
Holzer, Philipp
CHIMIA, 2017, 71 (10) : 716 - 721
[37] Inhibitors of the MDM2-p53 interaction as anticancer drugs
Hardcastle, Ian R.
DRUGS OF THE FUTURE, 2007, 32 (10) : 883 - 896
[38] An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinones
Anil, B.
Blackburn, E.
Blackburn, T.
Cully, S.
Liu, J.
Drummond, C. J.
Endicott, J. A.
Golding, B. T.
Griffin, R. J.
Haggerty, K.
Lunec, J.
Newell, D. R.
Revill, C. H.
Riedinger, C.
Watson, A. F.
Xu, Q.
Zhao, Y.
Hardcastle, I. R.
Noble, M. E. M.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : 91 - 92
[39] New chemical tools for disrupting the MDM2/p53 protein-protein interaction: Identification, synthesis and biological evaluation of a novel class of MDM2/p53 inhibitors
Pernazza, Daniele
Li, Xiaolong
Lawrence, Harshani R.
Guida, Wayne C.
DuBoulay, Courtney J.
Watts, Shawn
Sebti, Sayd M.
Chen, Jiandong
Lawrence, Nicholas J.
CANCER RESEARCH, 2011, 71
[40] The MDM2-p53 interaction
Moll, UM
Petrenko, O
MOLECULAR CANCER RESEARCH, 2003, 1 (14) : 1001 - 1008

← 1 2 3 4 5 →